Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. (CYBN) is a clinical-stage biopharmaceutical leader advancing novel psychedelic-based therapies for mental health conditions. This dedicated news hub provides investors and researchers with essential updates on the company's progress in developing innovative treatment solutions.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships that shape Cybin's research pipeline. Our curated collection includes official press releases detailing advancements in deuterated compound research, intellectual property achievements, and collaborative neuroscience initiatives.
Key updates cover FDA designations, preclinical study results, and patent filings that demonstrate Cybin's scientific rigor in psychedelic therapeutics development. The resource serves as a centralized tracking point for material events influencing the company's position in mental health innovation.
Bookmark this page for structured access to verified information about Cybin's therapeutic candidates and operational developments. Check regularly for objective updates on progress within the regulated biopharmaceutical research landscape.
Cybin has announced the election of Theresa Firestone to its board of directors during a shareholder meeting on August 16, 2021. A total of 45,681,073 common shares were represented, accounting for 30.77% of total shares. Key voting results include the appointment of Zeifmans LLP as auditor with 99.76% approval, setting the board size at six directors with 99.87% approval, and amendments to the equity incentive plan with 95.43% support. Additionally, a shareholder rights plan was approved to protect shareholders during potential takeover bids.
Cybin Inc. (NEO:CYBN) reported its unaudited financial results for Q1 ended June 30, 2021. The company raised over C$120M, including C$34M in August 2021. Key highlights include becoming the first psychedelic company listed on NYSE American, initiating a digital therapeutics platform, scaling European operations, and expanding its patent portfolio to 13 filings. Cybin also commenced a collaboration with TMS NeuroHealth Centers to advance research in psychedelic therapeutics. The company reported a net loss of C$14.7 million for the quarter.
Cybin Inc. (CYBN) announces that its subsidiary Adelia Therapeutics has met key milestones as stipulated in the December 2020 Transaction Agreement. Adelia will receive Class B common shares worth approximately CAD 475,292, which can be exchanged for Cybin common shares at a 10-to-1 ratio. The Class B shares will have a staggered exchange schedule, allowing only a portion to be converted before December 2023. This development illustrates Cybin's commitment to advancing psychedelic therapeutic solutions.
Cybin (NYSE:CYBN), a biotechnology company focused on psychedelic therapeutics, has announced that CEO Doug Drysdale will present virtually at Canaccord Genuity’s 41st Annual Growth Conference on August 10, 2021, at 3:30 PM ET. The presentation will be webcast live and available for playback for 90 days following the event. Cybin is dedicated to advancing psychedelic treatments for psychiatric disorders using innovative drug discovery and delivery methods. Forward-looking statements regarding their strategic branding, capital markets exposure, and drug development programs are included in the release.
Cybin, a biotechnology company focused on psychedelic therapeutics, has announced a new partnership with Catalent, the leader in drug delivery technologies. The agreement allows Cybin to utilize Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for its novel drug CYB003, aimed at treating resistant psychiatric disorders. This innovative delivery method promises improved pharmacokinetics by enabling pre-gastric absorption. The project begins in April 2021 with feasibility studies on various ODT formulations.
Cybin has successfully completed its 20th pre-clinical study and is advancing the proprietary psychedelic molecules CYB003 and CYB004 into Investigational New Drug (IND)-enabling studies. The studies utilized Cybin's technology and were executed rapidly through collaboration with partners. The company has initiated an API manufacturing contract and aims to address serious psychiatric conditions with these new candidates. Cybin boasts a discovery pipeline of over 50 proprietary psychedelic molecules, enhancing its position in the emerging psychedelic therapeutics market.
Cybin, a biotechnology company specializing in psychedelic therapeutics, announced that CEO Doug Drysdale will present a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 11:20 AM Eastern Time. The presentation will also be available via a live webcast for seven days afterward. Cybin is known for its innovative approaches to drug discovery, delivery systems, and psychiatric disorder treatments.
Cybin Inc. (NEO:CYBN, OTCQB:CLXPF), a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present a business update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference on March 17, 2021, at 3:30 PM ET. He will also participate in a panel discussion on psychedelics, which will be webcast live and available for replay for one week. Cybin leverages proprietary drug discovery and delivery systems to develop treatments for psychiatric disorders.
Cybin Inc. has commenced trading on the OTCQB under the symbol ‘CLXPF’ as of March 8, 2021. This move enhances the company's visibility and liquidity, allowing better access to both institutional and retail investors, as highlighted by CEO Doug Drysdale. The OTCQB, recognized by the SEC, offers stricter compliance and quality standards, which could positively impact investor confidence. Cybin continues to trade on the NEO Exchange under the symbol ‘CYBN’ and focuses on developing psychedelic therapeutics for mental health issues.
